|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Operating expenses | ||
| Research and development | ||
| Related Party | ||
| Nonrelated Party | ||
| Total research and development | ||
| General and administrative | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income, net | ||
| Interest income | ||
| Change in fair value of Series B preferred stock tranche rights liability | ||
| Total other income, net | ||
| Net loss before income taxes | ||
| Income tax expense | ||
| Net loss | ||
| Net Loss per share, basic (in usd per share) | ||
| Net Loss per share, diluted (in usd per share) | ||
| Weighted-average number common shares outstanding, basic (in shares) | ||
| Weighted-average number common shares outstanding, diluted (in shares) | ||
| Other comprehensive income: | ||
| Unrealized gain on marketable securities, net of tax | ||
| Total other comprehensive income | ||
| Total comprehensive loss |
Loading...
